Company leader
Kelly Huang, PhD
President and CEO
Elucid
Kelly Huang is president and chief executive of Elucid, a Boston company whose Plaque-IQ and FFR-IQ software read coronary CT scans to measure plaque and blood flow. He is a Stanford-trained chemical engineer who spent his career moving medical products from research into commercial use.
From Stanford to Johnson & Johnson
Huang earned a PhD in chemical engineering from Stanford University and began his career at Johnson & Johnson, where he spent about 15 years. In an interview with Scott Nelson, he said Johnson & Johnson invested in him and helped him move from research and development into general management.
Running Obalon and Cardea Bio
He later held senior roles at Endo Pharmaceuticals, where he was president of its HealthTronics division, and at Nestlé and Galderma. He became president, CEO, and a board director of Obalon Therapeutics, a publicly traded medical device company. Before Elucid he was chief operating officer of L-Nutra and then of Cardea Bio, a maker of biocompatible semiconductors that Paragraf acquired in 2023, according to Elucid's announcement of his appointment.
Leading Elucid
Elucid appointed Huang president and CEO in July 2024, as it prepared the commercial launch of Plaque-IQ. Since then the company raised a $55 million Series D in September 2026 and won FDA clearance for FFR-IQ in October 2026. Huang has described the goal as integrating anatomy, biology, and physiology so coronary artery disease care can be personalized, the way oncology moved away from one-size treatment.
"I'm never in a business to disintermediate the physician. I'm always in the business of enabling better clinical decision support for the physician," he told Scott Nelson. He also uses what he calls the Kitty Hawk moment, the Wright brothers' first 12-second flight, to argue that a young company should spend its resources proving the two or three things that show its technology works before optimizing anything else.